Earnings results for Allegion (NASDAQ:MNOV)
MediciNova, Inc. is estimated to report earnings on 10/23/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 0 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.05.
MediciNova last released its quarterly earnings results on July 28th, 2020. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.02. MediciNova has generated $0.00 earnings per share over the last year. MediciNova has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, October 23rd, 2020 based off prior year’s report dates.
Analyst Opinion on Allegion (NASDAQ:MNOV)
1 Wall Street analysts have issued ratings and price targets for MediciNova in the last 12 months. Their average twelve-month price target is $11.00, predicting that the stock has a possible upside of 103.33%. The high price target for MNOV is $11.00 and the low price target for MNOV is $11.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”
MediciNova has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $11.00, MediciNova has a forecasted upside of 103.3% from its current price of $5.41. MediciNova has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Allegion (NASDAQ:MNOV)
MediciNova does not currently pay a dividend. MediciNova does not have a long track record of dividend growth.
Insiders buying/selling: Allegion (NASDAQ:MNOV)
In the past three months, MediciNova insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,780.00 in company stock. Only 16.00% of the stock of MediciNova is held by insiders. Only 21.46% of the stock of MediciNova is held by institutions.
Earnings and Valuation of Allegion (NASDAQ:MNOV
Earnings for MediciNova are expected to decrease in the coming year, from ($0.37) to ($0.45) per share. MediciNova has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here